Document Detail


Adverse events associated with rofecoxib therapy: results of a large study in community-derived osteoarthritic patients.
MedLine Citation:
PMID:  12495363     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate the safety profile of rofecoxib, a selective cyclo-oxygenase-2 inhibitor, in patients with osteoarthritis who are receiving care in non-hospital practice settings.
DESIGN: All patients participating in a large 24-week, open-label, nonpharmacological intervention trial were given rofecoxib for painful osteoarthritis of the knee or hip. They started at a dose of 12.5mg once daily for the first month, with the option of increasing to 25mg daily thereafter, if needed for efficacy. Adverse events were closely monitored. We considered all adverse events that occurred during treatment and within 14 days of discontinuation of rofecoxib. PATIENT GROUP STUDIED: 2896 patients (861 males and 2035 females) were involved in the safety analysis. Their mean (SD) age was 66.8 (9.9) years, and 631 patients (21.8%) were aged >/=75 years. There were 913 patients (31.5%) with hypertension and 151 (5.2%) with diabetes mellitus at the start of the study; 78 patients (2.7%) had a prior medical history of angina and/or myocardial infarction. The mean (SD) duration of rofecoxib treatment was 139 (62) days.
RESULTS: A total of 519 patients (17.9%) discontinued rofecoxib. The main reasons for discontinuation were dyspepsia (4.4%), nausea (2.4%) and dizziness (2.1%). The annualised incidence rates (95% CI) of complicated and uncomplicated upper gastrointestinal ulcers, myocardial infarction, and stroke were 1.36 (0.76-2.23), 0.09 (0-0.50) and 0.45 (0.16-1.05), respectively.
CONCLUSION: This study conducted in conditions close to daily practice confirms that the use of rofecoxib is associated with a low rate of serious adverse events in patients with osteoarthritis.
Authors:
Bernard Bannwarth; Richard Trèves; Liana Euller-Ziegler; Denis Rolland; Philippe Ravaud; Maxime Dougados
Related Documents :
14705233 - The efficacy and cost effectiveness of n of 1 studies with diclofenac compared to stand...
25324443 - Management of testosterone therapy in adolescents and young men with hypogonadism: are ...
16965713 - Incubation period of hantavirus cardiopulmonary syndrome.
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Drug safety     Volume:  26     ISSN:  0114-5916     ISO Abbreviation:  Drug Saf     Publication Date:  2003  
Date Detail:
Created Date:  2002-12-23     Completed Date:  2003-05-08     Revised Date:  2014-11-17    
Medline Journal Info:
Nlm Unique ID:  9002928     Medline TA:  Drug Saf     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  49-54     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Aged
Ambulatory Care
Cyclooxygenase Inhibitors / administration & dosage,  adverse effects,  therapeutic use*
Drug Administration Schedule
Female
France
Humans
Lactones / administration & dosage,  adverse effects,  therapeutic use*
Male
Osteoarthritis, Hip / drug therapy*,  pathology
Osteoarthritis, Knee / drug therapy*,  pathology
Sulfones
Chemical
Reg. No./Substance:
0/Cyclooxygenase Inhibitors; 0/Lactones; 0/Sulfones; 0/rofecoxib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date.
Next Document:  Benefits and risks of pharmacotherapy for dysthymia: a systematic appraisal of the evidence.